Overview

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Status:
Completed

Trial end date:
2019-10-01

Target enrollment:

Participant gender:

Summary

This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc

Treatments:

Niacinamide
Sorafenib